BioNTech
Sign in to saveBioNTech SE ( ; or short for Biopharmaceutical New Technologies) is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
Key facts
- Company.name
- BioNTech SE
- Company.logo
- BioNTech logo.svg
- Company.image
- Mainz.BioNTechSE.20200731.jpg
- Company.image_caption
- Headquarters in Mainz
- Company.type
- Public company
- Company.industry
- Biotechnology
- Company.hq_location_city
- Mainz
- Company.hq_location_country
- Germany
- Company.num_locations
- 17
- Company.num_locations_year
- 2024
- Company.area_served
- Worldwide
- Company.products
- Pfizer-BioNTech COVID-19 vaccine, Immunotherapy and vaccine candidates
- Company.services
- Immunotherapy
- Company.revenue
- billion
- Company.revenue_year
- 2025
- Company.operating_income
- €−1.40 billion
- Company.income_year
- 2025
- Company.net_income
- €−1.14 billion
via Wikipedia infobox
Article
18 sectionsContents
- History
- Foundation (2008–2014)
- Expansion, Series A financing (2015–2018)
- Series B financing and Nasdaq IPO (2019)
- COVID-19 (since 2020)
- Oncology and international expansion (since 2021)
- Company structure
- Locations
- Management Board
- Therapeutic areas
- Oncology
- Infectious diseases
- Criticism
- Influence by the Chinese government
- Pricing of the COVID vaccine
- See also
- References
- External links
BioNTech SE ( ; or short for Biopharmaceutical New Technologies) is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.